KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Liabilities: 2010-2025

Historic Total Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $216.3 million.

  • Nektar Therapeutics' Total Liabilities fell 16.53% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year decrease of 16.53%. This contributed to the annual value of $243.1 million for FY2024, which is 8.96% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Total Liabilities is $216.3 million, which was down 6.68% from $231.7 million recorded in Q2 2025.
  • Nektar Therapeutics' Total Liabilities' 5-year high stood at $475.7 million during Q3 2021, with a 5-year trough of $216.3 million in Q3 2025.
  • Over the past 3 years, Nektar Therapeutics' median Total Liabilities value was $263.6 million (recorded in 2024), while the average stood at $263.1 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 40.87% in 2021, then decreased by 26.27% in 2023.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Total Liabilities stood at $437.7 million in 2021, then dropped by 21.41% to $344.0 million in 2022, then declined by 22.36% to $267.0 million in 2023, then dropped by 8.96% to $243.1 million in 2024, then fell by 16.53% to $216.3 million in 2025.
  • Its Total Liabilities was $216.3 million in Q3 2025, compared to $231.7 million in Q2 2025 and $242.5 million in Q1 2025.